Welcome to our dedicated page for CALCIMEDICA news (Ticker: CALC), a resource for investors and traders seeking the latest updates and insights on CALCIMEDICA stock.
CalciMedica Inc (CALC) is a clinical-stage biopharmaceutical company advancing novel therapies targeting calcium release-activated calcium (CRAC) channels for severe inflammatory conditions. This page provides centralized access to official news and developments regarding their innovative pipeline.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and scientific advancements. Key focus areas include acute pancreatitis, kidney injury, and pediatric pancreatic toxicity treatments currently in Phase 2 trials.
The resource features verified information on Auxora™ clinical data, partnership announcements, and research publications. Content is rigorously curated to support informed analysis while maintaining compliance with financial disclosure standards.
Bookmark this page for direct access to CALC's latest press releases and objective updates on their CRAC channel inhibition therapies. Check regularly for developments in this specialized area of immunomodulation research.
CalciMedica announced the closing of its merger with Graybug Vision, effective March 20, 2023, which allows its common stock to begin trading on the Nasdaq under the ticker CALC starting March 21, 2023. The merger gives CalciMedica approximately $34 million in cash reserves, anticipated to support operations through mid-2024. Key clinical milestones include Phase 2b results for its lead product, Auxora™, targeting acute pancreatitis, expected in Q4 2023. Additionally, a Research and Development Event will be held on April 27, 2023, to discuss Auxora’s potential in treating life-threatening inflammatory diseases.
FAQ
What is the current stock price of CALCIMEDICA (CALC)?
What is the market cap of CALCIMEDICA (CALC)?
